These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12879465)

  • 1. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis.
    Zeliadt SB; Penson DF; Albertsen PC; Concato J; Etzioni RD
    Cancer; 2003 Aug; 98(3):496-503. PubMed ID: 12879465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
    Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
    JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of the serum prostate specific antigen concentrations and Gleason histologic scores of black and white men with prostate carcinoma.
    Fowler JE; Bigler SA
    Cancer; 1999 Sep; 86(5):836-41. PubMed ID: 10463983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.
    Cross CK; Shultz D; Malkowicz SB; Huang WC; Whittington R; Tomaszewski JE; Renshaw AA; Richie JP; D'Amico AV
    J Clin Oncol; 2002 Jun; 20(12):2863-8. PubMed ID: 12065563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
    Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
    BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL.
    Fowler JE; Bigler SA; Farabaugh PB
    Cancer; 2002 Mar; 94(6):1661-7. PubMed ID: 11920526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.
    Henderson RJ; Eastham JA; Culkin DJ; Kattan MW; Whatley T; Mata J; Venable D; Sartor O
    J Natl Cancer Inst; 1997 Jan; 89(2):134-8. PubMed ID: 8998182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer.
    Wolf MS; Knight SJ; Lyons EA; Durazo-Arvizu R; Pickard SA; Arseven A; Arozullah A; Colella K; Ray P; Bennett CL
    Urology; 2006 Jul; 68(1):89-93. PubMed ID: 16844451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy.
    Bianco FJ; Wood DP; Grignon DJ; Sakr WA; Pontes JE; Powell IJ
    J Urol; 2002 Aug; 168(2):479-82. PubMed ID: 12131292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
    JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.
    Hoffman RM; Harlan LC; Klabunde CN; Gilliland FD; Stephenson RA; Hunt WC; Potosky AL
    J Gen Intern Med; 2003 Oct; 18(10):845-53. PubMed ID: 14521648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates.
    Pan CC; Lee JS; Chan JL; Sandler HM; Underwood W; McLaughlin PW
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1292-6. PubMed ID: 14630264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men.
    Eastham JA; Carver B; Katz J; Kattan MW
    Prostate; 2002 Mar; 50(4):236-40. PubMed ID: 11870801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians.
    Lotan Y; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2002; 5(2):111-4. PubMed ID: 12496998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
    Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
    Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.
    Lediju O; Ikuemonisan J; Salami SS; Adejoro O
    J Racial Ethn Health Disparities; 2019 Apr; 6(2):401-408. PubMed ID: 30506310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml.
    Fowler JE; Sanders J; Bigler SA; Rigdon J; Kilambi NK; Land SA
    J Urol; 2000 May; 163(5):1467-70. PubMed ID: 10751859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma.
    Paquette EL; Connelly RR; Sesterhenn IA; Zhang W; Sun L; Paquette LR; Greenspan R; McLeod DG; Moul JW
    Cancer; 2001 Nov; 92(10):2673-9. PubMed ID: 11745203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
    Kryvenko ON; Balise R; Soodana Prakash N; Epstein JI
    J Urol; 2016 Feb; 195(2):301-6. PubMed ID: 26341575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
    Fuletra JG; Kamenko A; Ramsey F; Eun DD; Reese AC
    Can J Urol; 2018 Feb; 25(1):9193-9198. PubMed ID: 29524974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.